In the United States,<unk>  is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. In the European Union,<unk>  is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people inadequately controlled on their maximal tolerated dose of<unk>  and a sulfonylurea; as triple combination therapy with a peroxisome proliferator-activated receptor (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in people inadequately controlled on their maximal tolerated dose of<unk>  and a PPAR agonist; and as add on to insulin as an adjunct to diet and exercise to improve glycemic control in people when stable dosage of insulin and<unk>  alone do not provide adequate glycemic control." In December 2020, the U.S. Food and Drug Administration (FDA) approved labeling changes stating that Januvia<unk> , Janumet<unk>  and<unk>  hydrochloride), and Janumet XR<unk>  and<unk>  hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in children aged 10 to 17 with type 2 diabetes. The drugs are approved to improve blood sugar control in adults aged 18 and older with type 2 diabetes.
Sitagliptin/metformin
Glibenclamide/metformin
Pioglitazone/metformin
Vildagliptin/metformin
Insulin degludec/liraglutide
Canagliflozin/metformin
Empagliflozin/metformin
Dapagliflozin/saxagliptin/metformin